Incidence:
It seems difficult to estimate the incidence of BPDCN because it is so rare and also because it has been such a difficult disease to diagnose definitively in the past. However, Pagano and colleagues in their study stated that it likely accounts for ˂ 1% of all hematologic malignancies. 5 BPDCN represent 0.7 percent of primary cutaneous skin lymphomas. 6 However, cutaneous lymphoma registries likely underestimate the true incidence of BPDCN because a small but significant proportion of patients present without skin lesions. 7 Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) 88 Epidemiology:
BPDCN has a male predominance; approximately 75% to 90% of cases occur in men.
Dr Andrew Lane in his study presented at the 2013 American Society of Hematology (ASH)
Annual Meeting described frequent, recurrent, somatic loss-of-function mutations in the splicing factor ZRSR2 in patients with BPDCN. This ZRSR2 is located on chromosome Xp22.1.
All patients with BPDCN in this study who had mutations in ZRSR2 (frameshift, nonsense, or splice site mutations) were males (10 patients) 8 .BPDCN might be more common in men owing to the involvement of the X chromosome and the location of ZRSR2. BPDCN also tends to occur in older patients. The median age at onset from 60 to 70 years and older. However, this disease can occur in females and children patients but it tends to be a disease of older men 9 with a male to female ratio of approximately 2.5:1
Clinical picture and presentation:
BPDCN is characterized by an aggressive behavior with rapid systemic dissemination, however some cases presented with indolent clinical picture with apparently isolated cutaneous involvement in the form of solitary or multiple lesions [10] [11] . 70% or more acquire skin lesions. The lesions can be mild and small, or they can be pronounced and extensive, covering the entire body in some cases often having a purplish discoloration. Other patients have a more traditional leukemic presentation, which means low blood cell counts and the presence of blasts in the bone marrow, such as are seen in acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL). 12 This cytopenia manifestations, particularly thrombocytopenia is due to bone marrow infiltration. 10-11 In the third type of presentation, patients have involvement of the lymph nodes, spleen, liver, or central nervous system, or they have extramedullary involvement in which the disease occurs outside the bone marrow.
In other words, this disease can present in essentially any location. 12
Diagnosis:
The diagnosis of BPDCN has evolved over time as clinical and pathologic technologies have improved. As with most leukemias and lymphomas, the diagnosis was once based on morphologic appearance of skin and bone marrow cells under the microscope 13 .
Typically, the malignant cell in BPDCN has abundant cytoplasm with a medium or low nucleusto-cytoplasmic ratio and displays faint basophilia without granulation. However, microvacuoles are commonly seen, most likely made of glycogen, arranged in a way to adopt a "pearl necklace" aspect beneath the nuclear membrane and characteristic pseudopod-like cytoplasmic expansions. 14 Malignant cells of BPDCN generally co-express CD4 + and CD56 + without co-expressing common lymphoid or myeloid lineage markers (Figure 1 A, cases of BPDCN showed co-expression of CD2, CD7, CD33, and/or CD117. 17 Identified key markers include CD123, the interleukin-3 receptor α-chain, T cell leukemia/lymphoma 1 (TCL1), blood dendritic cell antigen-2 (CD303/BDCA-2), and CD2-associated protein (CD2AP). 
Prognosis:
Despite an initial response to systemic chemotherapy, the disease regularly relapses and the median overall survival is (12-14 months). 10 Outcomes were poor regardless of the patient's age and regardless of a skin-only or a bone marrow presentation. Before the current era of targeted therapy, the patients with the best outcomes were those who were younger, had a complete remission, and received a stem cell transplant during first remission 9 . Some newer studies that have come out over the past 5 or 6 years suggest that the use of allogeneic 25 or, interestingly, autologous 26 transplant can improve median survival to 2 to 4 years.
Conventional Therapy:
Because of the rarity of BPDCN, no prospective data are available to define the most optimal frontline therapy. Limited cutaneous disease at presentation, without obvious nodal, bone marrow, and/or peripheral blood involvement, is not uncommon. However, even in such cases, local therapies (e.g., surgical excision or involved field radiation therapy) are ineffective, with systemic relapse anticipated in almost all cases, typically within 6 months. 27 Frontline treatment with regimens commonly used in non-Hodgkin lymphoma (eg, (range, 1 to 44) 22 .Dietrich et al. reported a CR rate of 83% in 6 patients treated with daunorubicin plus cytarabine followed by high-dose cytarabine (AML-like, n = 3) or an acute lymphoblastic leukemia-like induction regimen containing dexamethasone, methotrexate, vincristine, cyclophosphamide/ifosfamide, and idarubicin/daunorubicin (n = 3).
Unfortunately, the median time-to-disease relapse was only 7 months (range, 3 to 11) 29 .These 91 findings suggest that conventional chemotherapy does not appear to be sufficient by itself to ensure durable long-term remissions.
Autologous Hematopoietic Stem Cell Transplantation:
Several investigators used high-dose therapy and auto-HCT consolidation in BPDCN, with the goal of maximizing depth and duration of responses. 18 Suzuki et al. reported
outcomes of high-dose therapy followed by auto-HCT in 6 patients; 3 died from progression, and the remaining 3 were alive and disease-free at 11, 22, and 37 months after auto-HCT, respectively. 30 On the other hand, Reimer et al. reported relapses after auto-HCT in 3 of 4
cases at a median of 13 months. 18 Several limitations are inherent to these retrospective reports, including lack of centralized review to confirm this rare histology, heterogeneity in number and types of prior chemotherapies used, varying remission status at the time of transplantation, and a possible publication bias toward reporting favorable outcomes.
There are no available data to suggest an optimal conditioning regimen for auto-HCT in BPDCN (e.g., total body irradiation-based versus non-total body irradiation-containing regimens). The total body irradiation-based conditioning regimen used in the report by Reimer et al. was associated with disease relapse in 3 of 4 patients. 18 In the case series by Suzuki et al., 3 of 6 autografted cases were disease-free; however, the conditioning regimens were not specified. 30 It appears that patients with chemo-refractory disease and those with active central nervous system or bone marrow involvement at time of autografting are not likely to achieve durable remissions after auto-HCT 18 . These cases should ideally be considered for enrollment in clinical trials. However, in the absence of such trials, acknowledging the limitations and quality of available data, high-dose therapy and auto-HCT could be offered to patients with chemo-sensitive disease, preferably early in the disease course.
Allogenic Hematopoietic Stem Cell Transplantation:
Available data suggest that patients with BPDCN achieve long-term remissions, mostly if allografted in CR. 18,30 The European Group for Blood and Marrow Transplantation, recently in the largest registry study to date (n = 34), reported 3-year cumulative incidence of relapse, disease-free survival (DFS), and OS rates of 32%, 33%, and 41% respectively, after allo-HCT 25 .
Patients included in this study had a careful central review of their diagnosis to confirm this 
Targeting therapy:
Monoclonal antibodies, chimeric antigen receptor (CAR) T-cell therapies, and a class of drugs called dualtargeting agents or bispecific molecules are in development; they have the ability to target CD123, CD56, and other antigens that may be applicable to patients with BPDCN. These novel targeted agents should be studied for use in BPDCN over the next 1 to 2 years and could represent the next exciting direction in therapeutic drug development and targeting. 12 
